Elixirgen Therapeutics
Elixirgen Therapeutics is a clinical-stage biotechnology company focused on curing humanity’s ailments through innovations in cell and gene therapy, vaccine development, and platform technologies such as ZSCAN4 and controllable self-replicating RNA (c-srRNA). The company is dedicated to developing therapies for rare diseases, aging-associated diseases, and infectious diseases like COVID-19, leveraging proprietary technologies and clinical trials to bring innovative treatments to patients.
Industries
Nr. of Employees
small (1-50)
Elixirgen Therapeutics
Patents
Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
US-12060568-B2
View DetailsTemperature-based transient delivery of nucleic acids and proteins to cells and tissues
US-11421248-B2
View Details
Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
US-12060568-B2
View DetailsTemperature-based transient delivery of nucleic acids and proteins to cells and tissues
US-11421248-B2
View DetailsProducts
ZSCAN4-based autologous HSC therapy for telomere biology disorders
Autologous CD34+ hematopoietic stem cell product manufactured by ex vivo transient expression of ZSCAN4 using a non‑integrating, temperature-sensitive vector to elongate telomeres and potentially restore hematopoietic function.
Temperature-controllable self-replicating RNA vaccine platform
A controllable self-replicating RNA platform optimized for intradermal delivery and temperature-dependent expression to elicit T cell-mediated immunity with reported favorable safety profile in Phase I/II clinical testing.
Large-payload linear mRNA platform for expression of full-length large proteins
Linear mRNA platform engineered to encode large proteins in a single mRNA strand (demonstrated capacity >13 kb), enabling delivery of full-length proteins such as dystrophin in preclinical models.
ZSCAN4-based autologous HSC therapy for telomere biology disorders
Autologous CD34+ hematopoietic stem cell product manufactured by ex vivo transient expression of ZSCAN4 using a non‑integrating, temperature-sensitive vector to elongate telomeres and potentially restore hematopoietic function.
Temperature-controllable self-replicating RNA vaccine platform
A controllable self-replicating RNA platform optimized for intradermal delivery and temperature-dependent expression to elicit T cell-mediated immunity with reported favorable safety profile in Phase I/II clinical testing.
Large-payload linear mRNA platform for expression of full-length large proteins
Linear mRNA platform engineered to encode large proteins in a single mRNA strand (demonstrated capacity >13 kb), enabling delivery of full-length proteins such as dystrophin in preclinical models.
Services
Research collaborations with pharmaceutical partners to advance platforms for aging-associated diseases and rare genetic disorders, including technology transfer and joint R&D.
Co-development of modular Micro GMP units to enable decentralized processing and administration of cell therapies at clinical sites to reduce logistics and timelines.
Out-licensing of RNA vaccine rights to third-party commercial partners for broader regional or global commercialization.
Research collaborations with pharmaceutical partners to advance platforms for aging-associated diseases and rare genetic disorders, including technology transfer and joint R&D.
Co-development of modular Micro GMP units to enable decentralized processing and administration of cell therapies at clinical sites to reduce logistics and timelines.
Out-licensing of RNA vaccine rights to third-party commercial partners for broader regional or global commercialization.
Expertise Areas
- Cell and gene therapy development
- Autologous hematopoietic stem cell processing
- mRNA therapeutics and vaccine development
- Telomere biology and telomere-elongation therapeutics
Key Technologies
- Transient expression of ZSCAN4 in HSCs
- Temperature-controllable self-replicating RNA (c-srRNA)
- Linear/large-payload mRNA constructs (>13 kb)
- Non-integrating Sendai virus vectors for transient gene delivery
News & Updates
Elixirgen Therapeutics published early clinical results demonstrating telomere elongation in patients with Telomere Biology Disorders, indicating potential for treating aging-related diseases.
The FDA granted orphan drug designation to EXG-34217, a gene therapy for Telomere Biology Disorders, supporting its development for this rare disease.
The FDA granted RMAT designation to EXG-34217, facilitating accelerated development for treating Telomere Biology Disorders.
Research on telomere elongation in patients with rare telomere disorders using gene therapy.
FDA support for a gene therapy targeting rare telomere disorders.
Regulatory milestone to expedite development of telomere therapy.
Elixirgen Therapeutics published early clinical results demonstrating telomere elongation in patients with Telomere Biology Disorders, indicating potential for treating aging-related diseases.
The FDA granted orphan drug designation to EXG-34217, a gene therapy for Telomere Biology Disorders, supporting its development for this rare disease.
The FDA granted RMAT designation to EXG-34217, facilitating accelerated development for treating Telomere Biology Disorders.
Research on telomere elongation in patients with rare telomere disorders using gene therapy.
FDA support for a gene therapy targeting rare telomere disorders.
Regulatory milestone to expedite development of telomere therapy.